Introduction
Retinoic acid (RA), the most potent biologically active metabolite of vitamin A, induces cell differentiation and growth arrest in a variety of cell types through modifications of expression of subsets of RA-target genes (Bastien and Rochette-Egly, 2004) . The RA response is mediated by two families of nuclear receptors, the RARs (a, b, and g) and the RXRs (a, b, and g) which function as ligand-dependent heterodimeric RAR/RXR transcription activators (Laudet and Gronemeyer, 2002) .
Differentiation and proliferation are complex biological processes in which the Phosphoinositide 3-kinase (PI3K)/Akt signaling pathway also plays a pivotal role (Cantley, 2002; Brazil et al., 2004) . PI3K is composed of a p85 regulatory subunit and a p110 catalytic one (Cantley, 2002; Hanada et al., 2004) and is activated in response to a variety of growth factors which bind to specific transmembrane receptors with tyrosine kinase activity (RTK). Following tyrosine kinase stimulation, the p85a subunit interacts with the phosphorylated tyrosine residues of RTKs or adaptor proteins and mediates the activation and translocation of the p110 catalytic subunit to the cell membrane. Activated PI3K catalyses the formation of phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3) also named PIP3 (Vivanco and Sawyers, 2002) which mediate the translocation of Akt at the plasma membrane, where Akt is phosphorylated at Thr308 by PDK1 and at Ser473 by PDK2 Hanada et al., 2004; Sarbassov et al., 2005) and subsequently activated. Akt is the major downstream effector of PI3K signaling and has a number of downstream substrates that contribute to cell differentiation, proliferation and survival (Datta et al., 1999; Brazil et al., 2004) . PI3K activity is antagonized by PTEN (acronym for the Phosphatase and Tensin homolog) which dephosphorylates the 3 0 position of PIP3 to produce PI(4,5)P2 (Comer and Parent, 2002; Leslie and Downes, 2002) .
Since both the PI3K/Akt pathway and RA play critical roles in cell differentiation and proliferation, the objective of the present study was to investigate whether RA targets and/or requires the PI3K/Akt pathway. To this end, we took advantage of mouse embryocarcinoma cells (F9 cells) which constitute a well-established cell autonomous model system for investigating RA signaling as RA induces their differentiation and decreases their proliferation rate through modifications of expression of subsets of RA-target genes (Rochette-Egly and Chambon, 2001) . Here, we show that RA induces a biphasic effect on Akt activity with an early activation followed by an inhibition, both effects depending on the integrity of the RA pathway. The early activation of Akt results from an increase in PI3K activity and is determinant for F9 cells differentiation.
Results
RA has a biphasic effect on Akt activity, induction and inhibition When exposed to all trans RA, F9 cells differentiate into primitive endoderm-like cells within 48 h (Rochette-Egly and Chambon, 2001) . To establish whether RA targets the PI3K/Akt pathway in these cells, Akt activity has been analysed by immunoblotting with antibodies recognizing specifically Akt phosphorylated at S473 (P-S-Akt) and T308 (P-T-Akt). In response to RA, the amount of phosphorylated Akt increased at 24-48 h (Figure 1a Figure 1b , lane 4). The phosphorylation of Glycogen Synthase Kinase, GSK3 a/b, a target of Akt, also increased and decreased in parallel to Akt phosphorylation ( Figure 1a) . Similar results were obtained in an in vitro kinase assay using Akt immunopurified from F9 cells and purified recombinant GSK3 protein as a substrate (Figure 1b) , confirming that RA affects Akt activity.
As in F9 cells, most RA-induced events are transduced by RARg/RXRa heterodimers (Rochette-Egly and Chambon, 2001), we assessed whether the observed variations in Akt phosphorylation and activity were also related to an RA-induced process involving these heterodimers. With that aim, F9 cells were treated for 24 h with synthetic ligands selective for each RAR isotype in combination with a pan-RXR agonist. The increase in Akt phosphorylation that occurs at 24-48 h, was observed in response to either RA, 9cRA or to the RARg/pan-RXR agonists combination ( Figure 1c , lanes 2, 3 and 5) but not in response to the RARa/pan-RXR and RARb/pan-RXR combinations (Figure 1c , lanes 4 and 6), indicating that it involves RARg/RXRa heterodimers. The same conclusion was made for the decrease in Akt phosphorylation observed at 96 h ( Figure 1c , lanes 7-12). In line with this, in F9 cells knockout for RARg (RARg À/À F9 cells), no significant variation of Akt phosphorylation was observed in response to RA (Figure 1d ). Altogether, these results indicate that RA has a biphasic effect on Akt activity and that this process involves RARg/RXR heterodimers.
Both the activation and inhibition of Akt activity parallel PIP3 levels Akt phosphorylation and activity generally reflect the level of PIP3 and PI(3,4)P 2 (Scheid et al., 2002) which are determined by the balance between PI3K and lipid phosphatases PTEN and SHIP activities. Therefore, we investigated whether RA alters the amount of the upstream activators PIP 3 and PI(3,4)P 2 . After labeling with ( 32 P) orthophosphate, phospholipids were extracted, separated by thin layer chromatography and quantified by HPLC (Figure 2a) . In RA-treated F9 cells, PIP3 levels followed the profile of Akt activity with an increase (twofold) at 24 h (Figure 2b ), followed by a decrease (threefold) at 96 h (Figure 2c ). Note that PI(3,4)P 2 levels also decreased at 96 h but were not affected at 24 h. Collectively these results indicate that the biphasic effect of RA on Akt activity reflects the amounts of the upstream PIP3.
Early RA-induced activation of Akt results from PI3K activation via an increased expression of the p85a subunit To assess whether the changes in PIP3 levels reflect PI3K activity, we analysed the insulin response of the RA-treated F9 cells. The action of insulin is mediated through a specific transmembrane RTK and the subsequent activation of PI3K and Akt activities (Brazil et al., 2004) . F9 cells express insulin receptors as well as the adaptor protein IRS-1 (Puscheck et al., 1998) , and within minutes, insulin enhances Akt phosphorylation at S473 (Figure 3a , lanes 3 and 7). This effect was further enhanced when F9 WT cells were pretreated with RA for 24 h ( Figure 3a , lane 4), suggesting that the early RA-induced activation of Akt reflects an activation of PI3K. In line with this, the PI3K inhibitor LY294002 prevented the RA-induced increase in P-SAkt observed at 24 h ( Figure 3b ). Interestingly, the insulin response was also enhanced when the cells were pretreated with RA for 96 h ( Figure 3a , lane 8), suggesting that another pathway might be involved in the late inhibition of PIP3 and Akt observed in response to RA.
Then, we analysed whether RA alters the expression of the p85a regulatory and p110 catalytic subunits of PI3K. The expression of p85a increased within 24 h up to 96 h, both at the mRNA (Figure 3c Figure 3c and e, lanes 5-8), indicating that it results from a transcriptional process involving RARg/ RXR heterodimers. Consequently, the pool of p110/p85 heterodimers was enhanced as assessed by immunoprecipitation of the p110a catalytic subunit of PI3K ( Figure 3f ). In contrast, the expression of the p85b, p110a and p110 b subunits did not change significantly (Figure 3c and data not shown).
Then, RNA interference was used to assess whether the RA-induced increase in the expression of the p85a subunit of PI3K is required to induce Akt activity. Transfection of siRNA targeting p85a reduced endogenous p85a both at the mRNA (Figure 4a ) and protein levels (Figure 4b 
PI3K/Akt is necessary for RA-induced differentiation of mouse embryocarcinoma cells
To investigate whether the RA-induced activation of the PI3K/Akt pathway that occurs within 24-48 h is sufficient to affect F9 cells differentiation, we analysed the effects of the PI3K inhibitor LY294002 on the expression of differentiation markers (Taneja et al., 1997) . LY294002, which inhibits drastically RA-induced Akt activation (see Figure 3b) , caused a significant inhibition of the expression of the early endoderm differentiation marker, HNF1b, and of the late collagen IV and laminin markers, as assessed by quantitative RT-PCR (Figure 5a ).
The consequences of siRNA-mediated knockdown of Akt were also analysed. Transfection of F9 cells with a siRNA targeting Akt1, the predominantly expressed Akt isoform in most tissues (Chen et al., 2001) , reduced the expression of endogenous Akt at both the mRNA (Figure 5b ) and protein levels (Figure 5c ). Consequently, the RA-induced expression of the early and late differentiation markers was significantly decreased (Figure 5e ). Reciprocally, transfection of a plasmid expressing constitutively active Akt in a membranetargeted form with a src myristoylation signal (CA-Akt; Figure 5d ) caused a significant increase in the RAinduced expression of the differentiation markers (Figure 5f ).
Finally, the consequences of siRNA-mediated knockdown of the p85a subunit of PI3K were analysed. Transfection of sip85a which decreases only partially the RA-induced activation of Akt (see Figure 4c ) caused a significant inhibition of the expression of early endoderm differentiation markers including not only HNF1b but also HNF3a and GATA6, without affecting the late Collagen IV and Laminin markers (Figure 5g ). Collectively, these results indicate the importance of the activation of the PI3K/Akt pathway in the RA-induced differentiation of F9 cells. ) and the Head and Neck cancer cell line, SqCC/Y1, which responds to RA by the loss of squamous differentiation (Oridate et al., 1996) . However, no Akt inhibition was observed in RA-resistant cells such as the breast cancer cell line BT474 (Figure 6b ). Collectively, these results indicate that the RA-induced expression of p85a and the subsequent activation of Akt observed in F9 cells, would reflect to some extent the functionality of the p85a promoter and therefore would be cell specific. In contrast, the later inhibition of Akt would be a general process involved in the RA response.
Discussion
RA signaling is a complex and highly regulated process involving the early activation of several cellular signalings and the expression of subsets of target genes through RAR/RXR heterodimers. During the last years, considerable attention has been given to identify new RA-regulated genes, proteins, and pathways to gain insight into the mechanisms involved in the differentiating and growth inhibitory action of RA (Bastien and Rochette-Egly, 2004). Since the PI3K/Akt pathway plays as RA, a critical role in cell differentiation and proliferation, it was reasonable to assume that this pathway might mediate and/or contribute to the RA response. Here, by using mouse embryocarcinoma cells (F9 cell line) which constitute a well established cell autonomous model system for investigating RA signaling (Rochette-Egly and Chambon, 2001), we demonstrate that RA has a biphasic effect on the PI3K/Akt pathway, with an early activation followed by an inhibition. These results raise two important questions: what is the molecular mechanism by which RA activates and then inhibits the PI3K/Akt pathway and what would be the role of this biphasic regulation?
Early RA-induced activation of Akt correlates with PI3K activation and is a key determinant of F9 cells differentiation The current study demonstrates that, in F9 cells, the activity of Akt is markedly enhanced within 24 h of RA treatment. This effect correlates with PI3K activation as assessed by an increase in the levels of PIP3 and in the insulin response. It also depends, at least in part, on an increase in the expression of the p85a subunit. Note that the expression of the p85a subunit of PI3K and subsequently Akt activity had been also reported to be increased by peroxisome proliferator-activated receptors (PPARs) (Rieusset et al., 2001) , raising the hypothesis that p85a might be also a target for other nuclear receptors.
Using specific RAR agonists and F9 cells KO for RARg (RARg À/À cells), we demonstrated that the activation of the PI3K/Akt pathway involves RARg/ RXR heterodimers. In line with this, RA response elements (RARE) are present in the p85a promoter region (our unpublished observations). However, no transcriptional regulation of p85a was observed in several cancer cell types, suggesting that such a process might be cell specific. Indeed, in several carcinoma cells including breast cancer cells, the expression of a number of RA target genes is silenced by DNA methylation at the promoter region (Bovenzi et al., 1999) . Whether the promoter of the p85a gene is also hypermethylated would require further investigations. Note, however, that the gene encoding human p85a is located in chromosome 5q13.1 which is a critical locus that is disrupted or present aberrations in a subset of cancers (Kocki et al., 2003) .
We demonstrated that the early activation of the PI3K/Akt pathway is involved in the RA-induced differentiation of F9 cells. This is consistent with the emerging concept that PI3K/Akt signaling has diversified capacities and is apparently capable not only to promote cell growth but also to contribute in cell differentiation. Indeed, recent studies reported that activation of the PI3K/Akt pathway is required for the differentiation of myoblasts (Cabane et al., 2004; Gonzalez et al., 2004; Sarker and Lee, 2004) , keratinocytes (Calautti et al., 2005) as well as for the RA-induced differentiation of neuroblastoma cells (Lopez-Carballo et al., 2002) , HL60 cells (Ishida et al., 2004) , endometrial adenocarcinoma cells (Carter, 2003) and APL cells (Lal et al., 2005 ). The precise mechanisms through which the PI3K/Akt pathway contributes to cell differentiation have not been determined yet. However, one can suggest that this pathway regulates the transcription of some genes contributing to the differentiation process (Antonyak et al., 2002; Sarker and Lee, 2004) and/or to the growth and the survival of the newly differentiated cells (Antonyak et al., 2002; Di-Poi et al., 2002; Calautti et al., 2005) .
Later RA-induced decrease in Akt activity is PI3K independent The present study shows that RA also induces a late inhibition of the PI3K/Akt pathway, in F9 cells as well as in other cell types, in agreement with other reports (del Rincon et al., 2003; del Rincon et al., 2004; Farias et al., 2005) . Different hypothesis have been proposed concerning the mechanism through which RA inhibits the PI3K/Akt pathway but all the studies converged towards the conclusion that RA inhibits PI3K by preventing the association of the regulatory p85a with the p110 catalytic subunit and thus the formation of the active heterodimers. In contrast, in F9 cells, the downregulation of Akt does not seem to correlate with a decrease in PI3K activity, despite a decrease in PIP3 levels. Further studies are required to determine whether PIP3 and PI(3,4)P2 levels are downregulated via the activation of a phosphatase (Comer and Parent, 2002; Leslie and Downes, 2002) or by the p85a subunit independently of PI3K (Ueki et al., 2003) .
In conclusion, the current study describes a biphasic regulation of the PI3K/Akt pathway by RA, with an early activation followed with an inhibition. We propose a model where Akt activation would participate to the survival and the proliferation of the newly differentiated cells. Then when cells are differentiated and cease to grow, Akt activity is inhibited through a mechanism excluding PI3K, which will require further investigations. However, one cannot rule out that the kinases PDK1 and PDK2 involved in the phosphorylation of Akt and/or the expression of proteins interacting with Akt and regulating its activity (Maira et al., 2001; Hanada et al., 2004) , are also affected, increasing the complexity of the interplay between the RA and PI3K/ Akt signaling pathways. Nevertheless, our data establish that RA does target the PI3K/Akt pathway and that this pathwayparticipates in RA signaling. This finding may be of clinical relevance as in several cancers, aberrant PI3K activity (Blume-Jensen and Hunter, 2001; Kang et al., 2005) , has been correlated to RA-resistance which can be overcome by PI3K inhibitors (Tari et al., 2002; Neri et al., 2003) Materials and methods
Materials
RA and human recombinant insulin were from Sigma Aldrich Corporation (USA). The synthetic retinoid agonists specific for RARa (BMS 753), RARb (BMS 453) and RARg (BMS961) and the pan-RXR agonist (BMS 649) were as described (Taneja et al., 1997) . LY294002 and the antibodies Retinoic acid and the PI3K/Akt pathway J Bastien et al recognizing specifically Akt, Akt phosphorylated at S473 or at T308, GSK3 a/b and its phosphorylated form at S9 and S21 were from Cell Signaling Technology, Inc (USA). Goat polyclonal antibodies against b-actin were from Santa-Cruz Biotechnology (USA). Rabbit polyclonal p85a, p110a and Myc tag antibodies were from Upstate Biotechnology Inc. (USA) as well as the vector for constitutively active Akt with a Myc tag.
Cell lines F9 cells, either WT or RARg
À/À were cultured as described (Taneja et al., 1997) and transfected by using Lipofectamine 2000 (Invitrogen, USA) according to manufacturer's protocol. MCF7, SKBR3, BT474 and ZR-75-1 cells were maintained in RPMI supplemented with FCS (10%) according to standard conditions. Head and Neck Squamous Cancer Cells (SqCC/Y1 cell line) were provided by Dr Lotan and grown as described (Oridate et al., 1996) .
Short interfering (si) RNA
The 19-nt RNA oligonucleotides duplexes corresponding to Akt1 (NM_009652) and p85a (NM_011085) were purchased from Ambion Inc. (USA) and Dharmacon Inc. (Lafayette, CO, USA) respectively. Control nontargeting SiRNA were also from Ambion. F9 cells were double-transfected in consecutive days with 50 nM siRNAs and RA-treated 48 h after the first transfection.
Extract preparation, immunoblotting and Akt kinase assay Whole cell extracts were prepared and immunoblotted as described (Bour et al., 2005) . When a prior immunoprecipitation was required, extracts were prepared in nondenaturating buffer (150 mM Tris-HCl, pH 7.5, containing 1% Triton-100).
Akt kinase activity was measured in vitro, using the nonradioactive Akt kinase assay kit (Cell Signalling Technology Inc.,) according to the manufacturer's protocol, except that 200 mg of cell extracts were immunoprecipitated with immobilized Akt antibodies, and that 2 mg of GSK3 fusion protein were used as substrate.
RNA isolation and real-time quantitative RT-PCR Total RNAs were isolated and subjected to real-time quantitative RT-PCR as described (Bour et al., 2005) . Transcripts levels were normalized according to 36B4 transcripts, which are unresponsive to RA. The oligonucleotides for 36B4, RARg2 and HNF1b were as described (Bour et al., 2005) , as well as those for Collagen IV (Taneja et al., 1997) . Cell labeling and phospholipid analysis F9 cells were incubated in phosphate-free medium containing ( 32 P) orthophosphate (200 mCi/ml) for 16 h and lipids were extracted as described (Gratacap et al., 1998) and resolved by thin-layer chromatography (TLC). The spots corresponding to phosphatidylinosotol-3,4,5-triphosphate and phosphatidylinositol-3,4-biphosphate were scrapped off, deacylated and quantified by HPLC (Payrastre et al., 2001) . The elution profile of the various phosphoinositides was determined by using standards.
